Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.

ABSTRACT:

Objective

To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy.

Research design and methods

An on-drug/off-drug ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial to investigate posttrial changes in serum creatinine and cystatin C. Eligible participants were recruited into a prospective, nested, three-group study based on retrospective on-trial serum creatinine levels: fenofibrate case subjects (n = 321, ≥ 20% increase after 3 months of therapy); fenofibrate control subjects (n = 175, ≤ 2% increase); and placebo control subjects (n = 565). Serum creatinine and cystatin C were measured at trial end and 6-8 weeks after discontinuation

SUBMITTER: Mychaleckyj JC 

PROVIDER: S-EPMC3329840 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature